Our site may be slower due to heavy traffic from automated "bots" and AI crawlers. We're working to fix this.

Dana Meredith Chase

Title(s)Professor Of Clinical, Obstetrics and Gynecology
SchoolMedicine
Emaildmchase@mednet.ucla.edu
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Endometrial cancer therapy in 2026. Curr Opin Obstet Gynecol. 2026 Feb 01; 38(1):22-33. Rodriguez VE, Morrow M, Rajpara R, Chase DM. PMID: 41259235.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    2. Patient-reported outcomes of a randomized phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate risk, stage I/IIA cervical cancer patients treated with initial radical hysterectomy and pelvic lymphadenectomy (NRG/GOG-0263). Gynecol Oncol. 2025 Nov; 202:102-109. Chase DM, Huang HQ, Deng W, Koh WJ, Rodgers W, Small W, Albuquerque K, Mayadev J, Leath CA, Monk B, Kim BJ, Kim DY, Cho CH, Kim JW, No JH, Holman L, Stuckey A, Fabian D, Smick AH, Wenzel L, Gil K, Ryu SY. PMID: 41056581; PMCID: PMC12767459.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    3. Randomized phase III trial of adjuvant radiation versus chemoradiation in intermediate-risk, early-stage cervical cancer following radical hysterectomy and lymphadenectomy: results from NRG Oncology/GOG-263/KGOG 1008. Ann Oncol. 2025 Dec; 36(12):1514-1524. Ryu SY, Deng W, Albuquerque K, Koh WJ, Mayadev J, Heugel A, Kim BJ, Kim DY, Cho CH, Kim JW, No JH, Mannel RS, Miller K, Fabian D, Chase DM, Gil KM, Small W, Rodgers W, Leath CA, Monk BJ. PMID: 40947016; PMCID: PMC12721713.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    4. Mirvetuximab soravtansine in the ovarian cancer treatment landscape: influence of prior taxane exposure on outcomes. Int J Gynecol Cancer. 2025 Oct; 35(10):102016. Smick AH, Brennan L, Silverstein J, Salani R, Konecny G, Chase DM. PMID: 40916321.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Microbiome impacts quality of life in patients with endometrial cancer and benign gynecological conditions. Qual Life Res. 2025 Oct; 34(10):2935-2948. Gautam NJ, Jimenez NR, Laniewski P, Cui H, Roe DJ, Chase DM, Herbst-Kralovetz MM. PMID: 40682738; PMCID: PMC12535491.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. Real-world post-2020 first-line maintenance treatment patterns in patients with advanced ovarian cancer in the US. Future Oncol. 2025 Aug; 21(19):2495-2503. Chase DM, Kalilani L, Cooney MA, Kiss Z, Golembesky AK, Kobayashi M, Dayma M, Coskuncay E, Schilder JM. PMID: 40654327; PMCID: PMC12330229.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    7. Treatment patterns and outcomes by mismatch repair/microsatellite instability status among patients with primary advanced or recurrent endometrial cancer in the United States. Future Oncol. 2025 Aug; 21(18):2299-2310. Chase DM, Kobayashi M, Gomez P, Lubinga SJ, Chan JK. PMID: 40497451; PMCID: PMC12323428.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    8. Navigating complexities of polymorphic microbiomes in endometrial cancer. NPJ Biofilms Microbiomes. 2025 May 22; 11(1):85. Jimenez NR, Herman CR, Laniewski P, Cope E, Lee K, Mahnert ND, Chase DM, Caporaso JG, Herbst-Kralovetz MM. PMID: 40404643; PMCID: PMC12098703.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    9. Quality-adjusted time without symptoms of disease progression or toxicity of treatment in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel. Int J Gynecol Cancer. 2025 Aug; 35(8):101935. Chase DM, Herrstedt J, Miller EM, Gilbert L, Zub O, Mathews C, Angioli R, Teneriello M, Gropp-Meier M, Powell MA, Reyners AKL, Cloven NG, Eminowicz G, Gill SE, Mackowiak-Matejczyk B, Pothuri B, Samouëlian V, Jain A, Boone J, Bouberhan S, Trinidad J, Braly P, Buttin B, Backes FJ, Sawyer B, Antony G, Garside J, Allonby O, McCourt CK, Mirza MR. PMID: 40616865.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    10. Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial. Int J Gynecol Cancer. 2025 Jun; 35(6):101852. Valabrega G, Powell MA, Hietanen S, Miller EM, Novak Z, Holloway R, Denschlag D, Myers T, Thijs AM, Pennington KP, Gilbert L, Fleming E, Zub O, Landrum LM, Ataseven B, Gogoi R, Podzielinski I, Cloven N, Monk BJ, Sharma S, Herzog TJ, Stuckey A, Pothuri B, Secord AA, Chase D, Vincent V, Meyers O, Garside J, Mirza MR, Black D. PMID: 39322611.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsCTClinical Trials
    11. Suicide rates of cervical cancer patients in the United States - Who is most at risk? A retrospective study of 69,493 patients. J Cancer Policy. 2025 Jun; 44:100586. Hunsberger KS, Kapp DS, Chan JK, Irwin CM, Chase DM. PMID: 40252834.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    12. ROCC/GOG-3043: a randomized controlled trial of robotic versus open surgery for early-stage cervical cancer. Int J Gynecol Cancer. 2025 Jul; 35(7):101760. Leitao MM, Bixel KL, Chase DM, Quick A, McCormick C, Black D, Lim PC, Eskander RN, Gotlieb WH, LoCoco S, Martino MA, Walker JL, Copeland LJ, Monk BJ, Randall LM. PMID: 40188007.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    13. Niraparib as First-Line Maintenance Therapy in Patients with Stage III Ovarian Cancer and No Visible Residual Disease: AR1ZE Real-World Study. Oncol Ther. 2025 Mar; 13(1):253-262. Chase DM, Hanna M, Lim JT, Boyle TAC, Guinter M, Richey M, Patel K, Schilder JM, Hurteau JA, Golembesky AK. PMID: 39776033; PMCID: PMC11880480.
      View in: PubMed   Mentions:
    14. Clinical trial screening in gynecologic oncology: Defining the need and identifying best practices. Gynecol Oncol. 2025 Jan; 192:111-119. Castellano T, Lara OD, McCormick C, Chase D, BaeJump V, Jackson AL, Peppin JT, Ghamande S, Moore KN, Pothuri B, Herzog TJ, Myers T. PMID: 39644869.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    15. Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY). Gynecol Oncol. 2025 Jan; 192:40-49. Powell MA, Cibula D, O'Malley DM, Boere I, Shahin MS, Savarese A, Chase DM, Gilbert L, Black D, Herrstedt J, Sharma S, Kommoss S, Gold MA, Thijs AM, Ring K, Bolling MF, Buscema J, Gill SE, Nowicki P, Nevadunsky N, Callahan M, Willmott L, McCourt C, Billingsley C, Ghamande SA, He Z, Balas MM, Stevens S, Fleming E, Mirza MR. PMID: 39531903.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    16. Cervicovaginal lavages uncover growth factors as key biomarkers for early diagnosis and prognosis of endometrial cancer. Mol Biomed. 2024 11 08; 5(1):55. Harris HJ, Laniewski P, Cui H, Roe DJ, Chase DM, Herbst-Kralovetz MM. PMID: 39511039; PMCID: PMC11543965.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    17. Standard of care treatment for stage IVB cervical cancer: A systematic review and meta-analysis. Gynecol Oncol. 2024 Dec; 191:259-264. Hunsberger KS, Tewari KS, Monk BJ, Chase DM. PMID: 39471730.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    18. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial. Ann Oncol. 2024 Nov; 35(11):981-992. Monk BJ, Barretina-Ginesta MP, Pothuri B, Vergote I, Graybill W, Mirza MR, McCormick CC, Lorusso D, Moore RG, Freyer G, O'Cearbhaill RE, Heitz F, O'Malley DM, Redondo A, Shahin MS, Vulsteke C, Bradley WH, Haslund CA, Chase DM, Pisano C, Holman LL, Pérez MJR, DiSilvestro P, Gaba L, Herzog TJ, Bruchim I, Compton N, Shtessel L, Malinowska IA, González-Martín A. PMID: 39284381; PMCID: PMC11934258.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCTClinical Trials
    19. Patient Characteristics Associated with Time to Next Treatment in Patients with Ovarian Cancer Treated with Niraparib: The PRED1CT Real-World Study. Oncol Ther. 2024 Sep; 12(3):599-607. Chase DM, Shukla S, Moore J, Boyle TAC, Lim J, Perhanidis J, Hurteau JA, Schilder JM. PMID: 39097531; PMCID: PMC11333773.
      View in: PubMed   Mentions: 1  
    20. Advanced endometrial cancer-The next generation of treatment: A society of gynecologic oncology journal club clinical commentary. Gynecol Oncol Rep. 2024 Oct; 55:101462. Tillmanns T, Masri A, Stewart C, Chase D, Karnezis A, Chen LM, Urban R. PMID: 39210987; PMCID: PMC11357875.
      View in: PubMed   Mentions: 5  
    21. Cervicovaginal Metabolome and Tumor Characteristics for Endometrial Cancer Detection and Risk Stratification. Clin Cancer Res. 2024 Jul 15; 30(14):3073-3087. Lorentzen GM, Laniewski P, Cui H, Mahnert ND, Mourad J, Borst MP, Willmott L, Chase DM, Roe DJ, Herbst-Kralovetz MM. PMID: 38687603; PMCID: PMC11247321.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    22. A Plain Language Summary of "Dostarlimab for primary advanced or recurrent endometrial cancer". Future Oncol. 2025 Jan; 21(2):151-168. Mirza MR, Chase DM, Slomovitz BM, Christensen RD, Novák Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Hanker LC, Stuckey A, Boere I, Gold MA, Auranen A, Pothuri B, Cibula D, McCourt C, Raspagliesi F, Shahin MS, Gill SE, Monk BJ, Buscema J, Herzog TJ, Copeland LJ, Tian M, He Z, Stevens S, Zografos E, Coleman RL, Powell MA. PMID: 38990090; PMCID: PMC11792817.
      View in: PubMed   Mentions: 1     Fields:    
    23. Prescribers and patients drive maintenance therapy patterns in a community oncology practice: National guidelines versus the real-world experience. Gynecol Oncol Rep. 2024 Aug; 54:101440. Chase DM, Iadeluca L, Lim J, Tseng WY, Bulsara P, Patton G. PMID: 39040942; PMCID: PMC11261288.
      View in: PubMed   Mentions:
    24. A systematic review of stage IVA cervical cancer treatment: Challenges in the management of an understudied group. Gynecol Oncol. 2024 08; 187:120-127. Hunsberger KS, Treiman S, Monk BJ, Tewari KS, Taunk NK, Chase DM. PMID: 38759518.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    25. The impact of varying levels of residual disease following cytoreductive surgery on survival outcomes in patients with ovarian cancer: a meta-analysis. BMC Womens Health. 2024 Mar 15; 24(1):179. Chase DM, Mahajan A, Scott DA, Hawkins N, Kalilani L. PMID: 38491366; PMCID: PMC10941390.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    26. Cytochrome P450 inhibitor/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance setting. Gynecol Oncol Rep. 2024 Feb; 51:101332. Rimel BJ, Chase DM, Perhanidis J, Ghazarian AA, Du EX, Wang T, Song J, Golembesky AK, Hurteau JA, Kalilani L, Salani R, Monk BJ. PMID: 38362364; PMCID: PMC10867570.
      View in: PubMed   Mentions: 2  
    27. Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial. Gynecol Oncol. 2024 05; 184:168-177. Pothuri B, Han S, Chase DM, Heitz F, Burger RA, Gaba L, Van Le L, Guerra E, Bender D, Korach J, Cloven N, Churruca C, Follana P, DiSilvestro P, Baurain JF, Jardon K, Pisano C, Peen U, Mäenpää J, Gupta D, Bacqué E, Li Y, Compton N, Antonova J, Monk BJ, González-Martín A. PMID: 38325276.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    28. Radiation Therapy in Mismatch Repair-Proficient Patients With Isolated Nodal Recurrence. Int J Radiat Oncol Biol Phys. 2024 Feb 01; 118(2):320. Chase DM. PMID: 38220252.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    29. Health care services utilization in patients with ovarian cancer receiving PARP inhibitor maintenance treatment in a US community oncology setting. Gynecol Oncol. 2024 01; 180:79-85. Chase DM, Annavarapu S, Tseng WY, Shi J, Szamreta E, Monberg M. PMID: 38056115.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    30. Preoperative quality of life at time of gynecologic surgery: considerations for postoperative management. AJOG Glob Rep. 2023 Nov; 3(4):100275. Chase DM, McCann LD, Treuth A, Cui H, Laniewski P, Jimenez NR, Mahnert ND, Roe DJ, Herbst-Kralovetz MM. PMID: 38077226; PMCID: PMC10701442.
      View in: PubMed   Mentions: 1  
    31. Correlation between progression-free survival and overall survival in patients with ovarian cancer after cytoreductive surgery: a systematic literature review. Int J Gynecol Cancer. 2023 10 02; 33(10):1602-1611. Chase DM, Mahajan A, Scott DA, Hawkins N, Kalilani L. PMID: 37643825; PMCID: PMC10579502.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    32. Latest advances in immuno-oncology for endometrial cancer: single-agent and combination regimens. Curr Opin Obstet Gynecol. 2024 02 01; 36(1):1-8. Richardson M, Chase DM. PMID: 37792525.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    33. The power of hope: Views of Ovarian Cancer patients on how maintenance therapy Affects their Lives (VOCAL). Future Oncol. 2024 Jan; 20(2):83-94. Chase DM, Shukla S, Courcy J, Ellis H, Piercy J, Taylor-Whiteley T, Golembesky A, Wethington SL. PMID: 37701998.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    34. Factors Associated with Inpatient Narcotic Medication Usage after Robotic-assisted Laparoscopy. J Minim Invasive Gynecol. 2023 11; 30(11):926-930. Stewart C, Moreno A, Vo E, Bhattarai B, Farley J, Willmott L, Monk BJ, Chase DM. PMID: 37506878.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    35. Robotic-assisted gynecologic surgery in an older population: A comparison study. J Geriatr Oncol. 2023 07; 14(6):101533. Moore MS, Vo EH, Bhattarai B, Farley JH, Monk BJ, Willmott LJ, Chase DM. PMID: 37295288.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    36. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. N Engl J Med. 2023 06 08; 388(23):2145-2158. Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Novák Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Hanker LC, Stuckey A, Boere I, Gold MA, Auranen A, Pothuri B, Cibula D, McCourt C, Raspagliesi F, Shahin MS, Gill SE, Monk BJ, Buscema J, Herzog TJ, Copeland LJ, Tian M, He Z, Stevens S, Zografos E, Coleman RL, Powell MA, RUBY Investigators. PMID: 36972026.
      View in: PubMed   Mentions: 314     Fields:    Translation:HumansCellsCTClinical Trials
    37. Protein biomarkers in cervicovaginal lavages for detection of endometrial cancer. Biomark Res. 2022 Dec 02; 10(1):88. Laniewski P, Cui H, Mahnert ND, Mourad J, Borst MP, Willmott L, Chase DM, Roe DJ, Herbst-Kralovetz MM. PMID: 36461062; PMCID: PMC9717501.
      View in: PubMed   Mentions: 9  
    38. Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial. Ther Adv Med Oncol. 2022; 14:17588359221126149. Barretina-Ginesta MP, Monk BJ, Han S, Pothuri B, Auranen A, Chase DM, Lorusso D, Anderson C, Abadie-Lacourtoisie S, Cloven N, Braicu EI, Amit A, Redondo A, Shah R, Kebede N, Hawkes C, Gupta D, Woodward T, O'Malley DM, González-Martín A. PMID: 36172173; PMCID: PMC9511290.
      View in: PubMed   Mentions: 8  
    39. Impact of disease progression on health-related quality of life of advanced ovarian cancer patients - Pooled analysis from the PRIMA trial. Gynecol Oncol. 2022 09; 166(3):494-502. Chase DM, Marín MR, Backes F, Han S, Graybill W, Mirza MR, Pothuri B, Mangili G, O'Malley DM, Berton D, Willmott L, Baumann K, Coleman RL, Safra T, Heinzelmann-Schwarz V, Lorusso D, Karl FM, Woodward T, Monk BJ, Gonzalez-Martin A, PRIMA/ENGOT-OV26/GOG-3012 Investigators. PMID: 35851489.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    40. Cervicovaginal DNA Virome Alterations Are Associated with Genital Inflammation and Microbiota Composition. mSystems. 2022 04 26; 7(2):e0006422. Kaelin EA, Skidmore PT, Laniewski P, Holland LA, Chase DM, Herbst-Kralovetz MM, Lim ES. PMID: 35343798; PMCID: PMC9040584.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    41. Multi-omics data integration reveals metabolome as the top predictor of the cervicovaginal microenvironment. PLoS Comput Biol. 2022 02; 18(2):e1009876. Bokulich NA, Laniewski P, Adamov A, Chase DM, Caporaso JG, Herbst-Kralovetz MM. PMID: 35196323; PMCID: PMC8901057.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    42. Implicit biases in healthcare: implications and future directions for gynecologic oncology. Am J Obstet Gynecol. 2022 07; 227(1):1-9. Torres TK, Chase DM, Salani R, Hamann HA, Stone J. PMID: 35026128.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    43. Gastrointestinal symptoms and diagnosis preceding ovarian cancer diagnosis: Effects on treatment allocation and potential diagnostic delay. Gynecol Oncol. 2021 06; 161(3):832-837. Chase DM, Neighbors J, Perhanidis J, Monk BJ. PMID: 33814195.
      View in: PubMed   Mentions: 10     Fields:    
    44. Unwittingly biased: A note to gynecologic cancer providers. Gynecol Oncol. 2021 03; 160(3):646-648. Chase DM, Salani R, Farley J, Torres T, Stone J. PMID: 33485640.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    45. Management of nausea and vomiting from poly(ADP-ribose) polymerase inhibitor therapy for advanced ovarian cancer. Gynecol Oncol. 2020 11; 159(2):581-587. Eakin CM, Norton TJ, Monk BJ, Chase DM. PMID: 32972786.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    46. Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice. Gynecol Oncol. 2020 10; 159(1):112-117. Eakin CM, Ewongwo A, Pendleton L, Monk BJ, Chase DM. PMID: 32811682.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    47. Vaginal microbiota, genital inflammation, and neoplasia impact immune checkpoint protein profiles in the cervicovaginal microenvironment. NPJ Precis Oncol. 2020; 4:22. Laniewski P, Cui H, Roe DJ, Chase DM, Herbst-Kralovetz MM. PMID: 32802959; PMCID: PMC7398915.
      View in: PubMed   Mentions: 27  
    48. Uterine Inflammatory Myofibroblastic Tumor Showing an Atypical ALK Signal Pattern by FISH and DES-ALK Fusion by RNA Sequencing: A Case Report. Int J Gynecol Pathol. 2020 Mar; 39(2):152-156. Zarei S, Abdul-Karim FW, Chase DM, Astbury C, Policarpio-Nicolas MLC. PMID: 30741845.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    49. Features of the cervicovaginal microenvironment drive cancer biomarker signatures in patients across cervical carcinogenesis. Sci Rep. 2019 05 14; 9(1):7333. Laniewski P, Cui H, Roe DJ, Barnes D, Goulder A, Monk BJ, Greenspan DL, Chase DM, Herbst-Kralovetz MM. PMID: 31089160; PMCID: PMC6517407.
      View in: PubMed   Mentions: 58     Fields:    Translation:Humans
    50. Deciphering the complex interplay between microbiota, HPV, inflammation and cancer through cervicovaginal metabolic profiling. EBioMedicine. 2019 Jun; 44:675-690. Ilhan ZE, Laniewski P, Thomas N, Roe DJ, Chase DM, Herbst-Kralovetz MM. PMID: 31027917; PMCID: PMC6604110.
      View in: PubMed   Mentions: 155     Fields:    Translation:Humans
    51. Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women. Sci Rep. 2018 05 15; 8(1):7593. Laniewski P, Barnes D, Goulder A, Cui H, Roe DJ, Chase DM, Herbst-Kralovetz MM. PMID: 29765068; PMCID: PMC5954126.
      View in: PubMed   Mentions: 152     Fields:    Translation:HumansCells
    52. Uterine Microbiota: Residents, Tourists, or Invaders? Front Immunol. 2018; 9:208. Baker JM, Chase DM, Herbst-Kralovetz MM. PMID: 29552006; PMCID: PMC5840171.
      View in: PubMed   Mentions: 180     Fields:    Translation:HumansCells
    53. Poly(ADP-ribose) polymerase (PARP) inhibitors as treatment versus maintenance in ovarian carcinoma. Gynecol Oncol. 2017 07; 146(1):11-15. Graybill WS, Pothuri B, Chase DM, Monk BJ. PMID: 28392129.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    54. The development and use of vascular targeted therapy in ovarian cancer. Gynecol Oncol. 2017 05; 145(2):393-406. Chase DM, Chaplin DJ, Monk BJ. PMID: 28238563.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    55. Profile of olaparib in the treatment of advanced ovarian cancer. Int J Womens Health. 2016; 8:125-9. Chase DM, Patel S, Shields K. PMID: 27186080; PMCID: PMC4847603.
      View in: PubMed   Mentions: 2  
    56. Safety and efficacy of salvage nano-particle albumin bound paclitaxel in recurrent cervical cancer: a feasibility study. Gynecol Oncol Res Pract. 2016; 3:4. Minion LE, Chase DM, Farley JH, Willmott LJ, Monk BJ. PMID: 27231575; PMCID: PMC4880945.
      View in: PubMed   Mentions: 5  
    57. The Application and Outcome of Standard of Care Treatment in Elderly Women with Ovarian Cancer: A Literature Review over the Last 10 Years. Front Oncol. 2016; 6:63. Gibson SJ, Fleming GF, Temkin SM, Chase DM. PMID: 27047797; PMCID: PMC4805611.
      View in: PubMed   Mentions: 21  
    58. Disparities in Vulvar Cancer Reported by the National Cancer Database: Influence of Sociodemographic Factors. Obstet Gynecol. 2015 Oct; 126(4):792-802. Chase DM, Lin CC, Craig CD, Fedewa SA, Virgo KS, Farley JH, Halpern M, Monk BJ. PMID: 26348176.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    59. Retrospective review of symptoms and palliative care interventions in women with advanced cervical cancer. Gynecol Oncol. 2015 Dec; 139(3):553-8. Kim YJ, Munsell MF, Park JC, Meyer LA, Sun CC, Brown AJ, Bodurka DC, Williams JL, Chase DM, Bruera E, Ramondetta LM. PMID: 26432043; PMCID: PMC8765286.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    60. Factors associated with grade 3 or 4 treatment-related toxicity in women with advanced or recurrent cervical cancer: an exploratory analysis of NRG Oncology/Gynecologic Oncology Group trials 179 and 204. Int J Gynecol Cancer. 2015 Feb; 25(2):303-8. Chase DM, Kauderer J, Wenzel L, Ramondetta L, Cella D, Long HJ, Monk BJ. PMID: 25405577; PMCID: PMC4506195.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    61. Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2. Gynecol Oncol. 2015 Apr; 137(1):86-92. Minion LE, Dolinsky JS, Chase DM, Dunlop CL, Chao EC, Monk BJ. PMID: 25622547.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    62. Neurotoxicity in ovarian cancer patients on Gynecologic Oncology Group (GOG) protocol 218: characteristics associated with toxicity and the effect of substitution with docetaxel: an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Feb; 136(2):323-7. Chase DM, Huang H, Foss CD, Wenzel LB, Monk BJ, Burger RA. PMID: 25529832; PMCID: PMC4520309.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    63. Protein profiling of ovarian cancers by immunohistochemistry to identify potential target pathways. Gynecol Oncol Res Pract. 2014; 1:4. Foss CD, Dalton HJ, Monk BJ, Chase DM, Farley JH. PMID: 27231557; PMCID: PMC4877732.
      View in: PubMed   Mentions: 1  
    64. Updates on drug discovery in ovarian cancer. Gynecol Oncol Res Pract. 2014; 1:3. Gibson SJ, Tewari KS, Monk BJ, Chase DM. PMID: 27231556; PMCID: PMC4878024.
      View in: PubMed   Mentions: 4  
    65. Appropriate use of complementary and alternative medicine approaches in gynecologic cancers. Curr Treat Options Oncol. 2014 Mar; 15(1):14-26. Chase DM, Gibson SJ, Sumner DA, Bea JW, Alberts DS. PMID: 24398574.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    66. Simultaneous characterization of somatic events and HPV-18 integration in a metastatic cervical carcinoma patient using DNA and RNA sequencing. Int J Gynecol Cancer. 2014 Feb; 24(2):329-38. Liang WS, Aldrich J, Nasser S, Kurdoglu A, Phillips L, Reiman R, McDonald J, Izatt T, Christoforides A, Baker A, Craig C, Egan JB, Chase DM, Farley JH, Bryce AH, Stewart AK, Borad MJ, Carpten JD, Craig DW, Monk BJ. PMID: 24418928; PMCID: PMC3921261.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    67. Cognitive impairment in gynecologic cancers: a systematic review of current approaches to diagnosis and treatment. Support Care Cancer. 2014 Jan; 22(1):279-87. Craig CD, Monk BJ, Farley JH, Chase DM. PMID: 24212261.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    68. Methylation of human papillomavirus 16, 18, 31, and 45 L2 and L1 genes and the cellular DAPK gene: Considerations for use as biomarkers of the progression of cervical neoplasia. Virology. 2014 Jan 05; 448:314-21. Kalantari M, Osann K, Calleja-Macias IE, Kim S, Yan B, Jordan S, Chase DM, Tewari KS, Bernard HU. PMID: 24314662; PMCID: PMC4051423.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    69. Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer. Crit Rev Oncol Hematol. 2013 May; 86(2):161-75. Monk BJ, Dalton H, Farley JH, Chase DM, Benjamin I. PMID: 23137764.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimals
    70. Sexual function of patients with endometrial cancer enrolled in the Gynecologic Oncology Group LAP2 Study. Int J Gynecol Cancer. 2012 Nov; 22(9):1624-33. Carter J, Huang H, Chase DM, Walker JL, Cella D, Wenzel L. PMID: 23095778; PMCID: PMC3536465.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    71. The challenge of follow-up in a low-income colposcopy clinic: characteristics associated with noncompliance in high-risk populations. J Low Genit Tract Dis. 2012 Oct; 16(4):345-51. Chase DM, Osann K, Sepina N, Wenzel L, Tewari KS. PMID: 22622340; PMCID: PMC4293035.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    72. Changes in tumor blood flow as measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) may predict activity of single agent bevacizumab in recurrent epithelial ovarian (EOC) and primary peritoneal cancer (PPC) patients: an exploratory analysis of a Gynecologic Oncology Group Phase II study. Gynecol Oncol. 2012 Sep; 126(3):375-80. Chase DM, Sill MW, Monk BJ, Chambers MD, Darcy KM, Han ES, Buening BJ, Sorosky JI, Fruehauf JP, Burger RA. PMID: 22683587.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    73. Quality-of-life results used to endorse changes in standard of care for recurrent platinum-sensitive ovarian cancer. Expert Rev Pharmacoecon Outcomes Res. 2012 Jun; 12(3):279-81. Chase DM, Wenzel LB, Monk BJ. PMID: 22812551; PMCID: PMC4920474.
      View in: PubMed   Mentions:    Fields:    
    74. Quality of life and survival in advanced cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 May; 125(2):315-9. Chase DM, Huang HQ, Wenzel L, Cella D, McQuellon R, Long HJ, Moore DH, Monk BJ. PMID: 22307062.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    75. Disparities in the allocation of treatment in advanced ovarian cancer: are there certain patient characteristics associated with nonstandard therapy? Obstet Gynecol. 2012 Jan; 119(1):68-77. Chase DM, Fedewa S, Chou TS, Chen A, Ward E, Brewster WR. PMID: 22183213.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    76. Health-related quality of life in ovarian cancer patients and its impact on clinical management. Expert Rev Pharmacoecon Outcomes Res. 2011 Aug; 11(4):421-31. Chase DM, Wenzel L. PMID: 21831023; PMCID: PMC4920475.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimals
    77. Recruitment and retention results for a population-based cervical cancer biobehavioral clinical trial. Gynecol Oncol. 2011 Jun 01; 121(3):558-64. Osann K, Wenzel L, Dogan A, Hsieh S, Chase DM, Sappington S, Monk BJ, Nelson EL. PMID: 21402400; PMCID: PMC4572839.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    78. Drug discovery in ovarian cancer. Recent Pat Anticancer Drug Discov. 2010 Nov; 5(3):251-60. Chase DM, Mathur N, Tewari KS. PMID: 20524931.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    79. Assessment and significance of quality of life in women with gynecologic cancer. Future Oncol. 2010 Aug; 6(8):1279-87. Chase DM, Watanabe T, Monk BJ. PMID: 20799874.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    80. Recombination of human papillomavirus-16 and host DNA in exfoliated cervical cells: a pilot study of L1 gene methylation and chromosomal integration as biomarkers of carcinogenic progression. J Med Virol. 2010 Feb; 82(2):311-20. Kalantari M, Chase DM, Tewari KS, Bernard HU. PMID: 20029805.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    81. Severe fetal skull fracture and death subsequent to a motor vehicle crash with frontal airbag deployment. J Trauma. 2009 Dec; 67(6):E220-1. Nguyen CS, Chase DM, Wing DA. PMID: 20009656.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    82. Socioeconomic factors may contribute to neoadjuvant chemotherapy use in metastatic epithelial ovarian carcinoma. Gynecol Oncol. 2009 Dec; 115(3):339-42. Chase DM, Rincon A, Deane M, Tewari KS, Brewster WR. PMID: 19772939.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    83. Colposcopy to evaluate abnormal cervical cytology in 2008. Am J Obstet Gynecol. 2009 May; 200(5):472-80. Chase DM, Kalouyan M, DiSaia PJ. PMID: 19375565.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    84. Preoperative diagnosis of ovarian malignancy: preliminary results of the use of 3-dimensional vascular ultrasound. Int J Gynecol Cancer. 2009 Apr; 19(3):354-60. Chase DM, Crade M, Basu T, Saffari B, Berman ML. PMID: 19407559.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    85. A clinical pathway for postoperative management and early patient discharge: does it work in gynecologic oncology? Am J Obstet Gynecol. 2008 Nov; 199(5):541.e1-7. Chase DM, Lopez S, Nguyen C, Pugmire GA, Monk BJ. PMID: 18513685.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    86. Supportive care for women with gynecologic cancers. Expert Rev Anticancer Ther. 2008 Feb; 8(2):227-41. Chase DM, Monk BJ, Wenzel LB, Tewari KS. PMID: 18279064.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    Dana's Networks
    Concepts (289)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (13)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-21-g9d46e6c4 on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California